

## Review

# DNAzyme technology and cancer therapy: cleave and let die

Crispin R. Dass,<sup>1</sup> Peter F.M. Choong,<sup>1,2</sup> and Levon M. Khachigian<sup>3</sup>

<sup>1</sup>Department of Orthopaedics, St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia; <sup>2</sup>Bone and Soft Tissue Sarcoma Service, Peter MacCallum Cancer Centre, Melbourne, Australia; and <sup>3</sup>Centre for Vascular Research, Department of Pathology, School of Medical Sciences, The University of New South Wales and Department of Haematology, Prince of Wales Hospital, Sydney, Australia

### Abstract

Novel molecules are constantly being discovered and developed to find better means of managing debilitating and fatal diseases, which include cancer in its multiple forms. Among these molecules, and as a direct consequence of a better understanding of the molecular basis of diseases, are those falling within the class of gene therapeutics. Among these players, deoxyribozymes (DNAzymes) have come a long way from being just another analytic tool available to molecular biologists. Recent studies have shown the potential DNAzymes to serve as drugs both in cell-based assays and preclinical models of cancer. It is anticipated that with the development of smart delivery systems for DNAzymes, better pharmacokinetics and pharmacodynamics will be possible, expediting DNAzyme march toward the clinic. Also, the ability of DNAzymes to yield to such phenomena as light-induced activation may be exploited for targeted therapy. This review documents the rise of DNAzymes in the fight against cancer and serves as a forecast for this promising biotechnology in this context. [Mol Cancer Ther 2008;7(2):243–51]

### Introduction

Over the past decade, our appreciation of the pathogenesis of human disease has rapidly evolved particularly due to recent significant advances in genomics, which have shifted the focus of researchers onto the intricate molecular and

cellular pathways that constitute a disease. This is in part largely due to the Human Genome Organisation gene sequencing project, and even more so, the almost readily available and applied gene microarray tools available to researchers. These tools have dramatically altered the pace with which tumor samples are analyzed for temperospatial expression of genes on a global scale. The information technology age has also significantly helped in expediting research efforts that were unimaginable even as recently as 5 years ago.

Hand-in-hand with these findings, and probably more importantly, we have acquired the capacity to selectively attenuate the expression of specifically targeted genes both as a means of dissecting molecular function as well as switching genes down or off to modulate disease outcome. As such, strategies to specifically knockdown gene expression have recently received considerable attention, and these include antisense, oligodeoxynucleotide decoys, small interfering RNA, aptamers, and the catalytic ribozymes and DNAzymes. Technologies for gene modulation, once items of sheer curiosity and limited potential, have now given way to an oligonucleotide-based therapeutic. Approved by the Food and Drug Administration in 1998 was Isis Pharmaceuticals' Vitravene (fomivirsen), a treatment for cytomegalovirus retinitis in immunocompromised patients, such as those with AIDS (1).

A second possible candidate, Genasense (Oblimersen), manufactured by Genta, Inc., was initially intended for use in treating relapsed or refractory chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide. Genasense is directed against the *bcl-2* oncogene. The molecule has also recently acquired orphan drug status for treating melanoma in Australia in combination with decarbazine (2).

However, it is nearly a decade since the approval of the initial antisense drug, and despite the best efforts of large biotechnology corporations to shepherd lead candidates through the development pipeline, there has been a relative paucity of such drugs emerging. However, the ability to specifically target gene expression in such a novel way means that if a potent molecule is found, then it may well be useful against various pathologies as will be discussed below.

### Catalytic Nucleic Acids—Brief Overview

Through Watson-Crick-based interactions with complementary sequences mediated by such attributes as flexible binding and discrimination of nucleic acid substrates,

Received 7/29/07; revised 11/21/07; accepted 12/19/07.

**Requests for reprints:** Crispin R. Dass, Department of Orthopaedics, St. Vincent's Hospital Melbourne, Fitzroy, Vic 3065, Australia. Phone: 61-3-9288-3954; Fax: 61-3-9416-3610. E-mail: [crispin.dass@svhm.org.au](mailto:crispin.dass@svhm.org.au)

Copyright © 2008 American Association for Cancer Research.

doi:10.1158/1535-7163.MCT-07-0510

ribozymes perform catalytic reactions with great precision. Because the initial designing of RNA-cleaving catalytic RNA (3), this capability led by ribozymes has rapidly progressed to a limited number of clinical trials (4). As these ribozymes can be encoded and transcribed from DNA, much of this development has been advanced by enhanced vector designs used in other forms of gene therapy that rely on gene overexpression. On the other hand, substantial progress has also been made in the synthesis and delivery of ribozymes (i.e., not within expressible gene vectors). It was a decade later that DNAzymes entered the scene of nucleic acid-mediated catalysis.

These DNAzyme molecules, discovered in 1994 by Ronald Breaker and Gerald Joyce (5), and exemplified by the 10-23 deoxyribozyme (6), essentially combine the benefits of highly sequence-specific RNase-independent RNA destruction, with the relatively stable chemistries used in oligodeoxynucleotide-based antisense reagents. Perhaps a major obstacle in the further development of these technologies is a phenomenon that requires substantial development efforts invested in drugs of various classes, the uphill battle to effect cellular delivery in a targeted manner. This challenge is being met with a multidisciplinary approach with the hope that a greater understanding of each step of this process will enhance DNAzyme pharmacodynamics. Such diverse fields as gene vector design, biomolecular and chemical engineering, drug delivery, pharmaceuticals, membrane biophysics, anatomy, and physiology, are coming together to present tangible solutions to enhance DNAzyme efficacy.

It was 30 years ago when it was first reported that nucleic acids could be used to down-regulate gene expression via a direct and highly specific interaction with the transcript (7). Thereafter, Stephenson and Zamecnik (8) exhibited the capacity of antisense molecules to inhibit viral replication. Since then, the field of nucleic acid-based therapies has rapidly blossomed with numerous gene targets and methods comprising of both naturally occurring and synthetic molecules that have been tested both *in vitro* and *in vivo* against different pathologies with reasonable to dramatic success. Currently, a number of these approaches are being evaluated in human and larger animal trials and are poised to offer better therapies in the future.

Essential criteria dictating the usefulness of a DNAzyme are that the DNAzyme should specifically cleave its target mRNA, the target gene should play a key (noncompensatable) role in the disease process, target gene inhibition should not adversely influence normal physiologic processes, the DNAzyme should be capable of being carried and delivered by a variety of vehicles (if free delivery is suboptimal), the DNAzyme is amenable to chemical modification to avoid degradation, and the DNAzyme should not cause nonspecific (off target) effects. This review will focus exclusively on DNAzyme strategies, and the reader is referred to excellent reviews by others for updates on antisense (9), small interfering RNA (10), and ribozyme (4) technologies and the utility of these molecules against cancer.

## Background to DNAzymes


Unlike ribozymes, which have been widely hypothesized to have carried genetic information and performed catalysis during the primordial "RNA World" (11), catalytic DNA has not been observed in nature and all existing molecules have been derived by *in vitro* selection processes. The most well-characterized DNAzyme is the 10-23 subtype comprising a cation-dependent catalytic core of 15 deoxyribonucleotides (6) that binds to and cleaves its target RNA between an unpaired purine and paired pyrimidine through a de-esterification reaction (Fig. 1). Sequence conservation in the border regions of the catalytic core is important for the maintenance of catalytic activity (12). This core is flanked by complementary binding arms of 6 to 12 nucleotides in length, which, via Watson-Crick hybridization, confer specificity for the targeted mRNA. Once the target is bound, catalysis proceeds and the mRNA strand is nicked into two. DNAzymes are purported to be just as efficient as protein enzymes at cleaving RNA (13).

In terms of biological specificity, DNAzymes with nonsense or mismatch sequences in the binding arms, or with point mutations in the catalytic core rendering the DNAzyme enzymatically inactive, can serve as important controls when assessing specificity (Fig. 2). We commonly use the entity of the "scrambled DNAzyme," in which the nucleotides in the binding arms of the DNAzyme are jumbled. This produces a molecule of identical size and same net charge with a binding sequence that is not matched to the target gene.

The 10-23 DNAzyme, named because of its selection process *in vitro*, catalyses sequence-specific RNA cleavage in a manner akin to the hammerhead ribozyme and hence has substantial utility as a gene silencing agent. *In vitro* cleavage experiments have shown that the 10-23 DNAzyme is highly specific and in fact quite sensitive to small changes in target sequence (14, 15). Imperatively, DNAzyme activity is dependent on the prevailing secondary structure of long target RNA at the cleavage site (15). For this reason, it is important to test a range of synthesized molecules to identify those that display a high level of activity against biologically relevant target molecules. The journey from *in vitro* cleavage kinetics to cell culture assessment (down-regulation of the target gene, plus phenotypic changes) to evaluation *in vivo* (in clinically relevant models demonstrating efficacy and minimal toxicity) can be arduous and is usually accompanied by a large attrition rate of candidate molecules.

## Stability of DNAzyme Molecules

A number of structural modifications have been used to enhance stability as well as improve potency of DNAzymes. An important, commonly used modification is the incorporation of a 3'-3' inverted nucleotide at the 3' terminus of the DNAzyme to prevent exonuclease degradation. This can dramatically increase stability of the molecule extending the half-life from minutes to >21 h in human serum as we have shown (16). Additionally, DNAzymes



**Figure 1.** DNAzyme mechanistic. 1, the DNAzyme binds to its complementary target mRNA. 2, cleavage occurs. 3, scrambled control for DNAzyme depicted in 1; note arms with different sequences. 4, inverted core control of DNAzyme with the catalytic core sequence in reverse orientation. 5, mismatch control, where one base is altered on one of the arms of the DNAzyme. 6, mutated core control, where one base is altered within the catalytic core sequence.

with this modification can remain functionally intact for at least 24 to 48 h after exposure to serum compared with its unmodified counterpart (17) with little change in the cleavage kinetics (18). Phosphorothioate linkages enhance


stability by rendering the oligonucleotide more resistant to endogenous nucleases, and have been used with DNAzymes (19), although such alterations in antisense oligodeoxynucleotides have been associated with toxicity (20), immunologic responsiveness (21), and increased affinity for cellular proteins resulting in sequence-independent effects (22, 23). Thus, phosphorothioate modifications are seldom used for DNAzyme work and have been used with decreasing frequency over the past 5 years.

Locked nucleic acids have been attractive monomers for modifying DNAzymes (24–26) in efforts to increase binding affinity. Locked nucleic acid bases comprise a 2'-O-4-C methylene bridge that locks in a C3'-endo conformation (27), effectively increasing affinity for complementary sequences (28, 29). The advantages of locked nucleic acid include increased thermal stability of duplexes toward complementary DNA or RNA, stability toward 3'-exonucleolytic degradation, and greater solubility due to structural similarities to nucleic acids (30, 31). Locked nucleic acid incorporation into DNAzymes, however, has been found to influence both catalytic activity under single turnover conditions (24, 26) and biological potency (26, 32). Because DNAzymes with an inverted nucleotide at the 3' end are catalytically more efficient compared with their locked nucleic acid-modified counterparts due to a faster product release rate (25, 33), they are still highly recommended for usage.

### Activity of DNAzymes against Cancer Cells *In vitro*

Demonstrating cleavage kinetics with DNAzymes in a cell-free system is a valuable way to narrow the choice of molecules one needs to test in *in vitro* assays, mainly for successful down-regulation of the specific mRNA target. Having successfully done this, one needs to screen the DNAzymes through selective cell-based assays that help identify the effects of such down-regulation on cell physiology. A good starting point assay for selection of anticancerous DNAzymes is that of proliferation, which may indicate that an apoptotic assay needs to be done if positive (reduced cell proliferation) is noted. For more sophisticated assays, such as those for colony formation or invasion through a biological matrix (34), results are more helpful, and may even help to explain findings in subsequent *in vivo* studies.

The first usage of a DNAzyme against a target in cancer cells was by Wu and colleagues (35) who used three DNAzymes against the two variants of the p210 *bcr-abl* gene (splice 1, b3a2; splice 2, b2a2) and the p190 variant (ela2). Bcr-Abl is implicated in >95% of chronic myeloid leukemia patients and 20% to 30% of adults with acute lymphoblastic leukemia. Mutated DNAzymes, in which only one critical base had been altered, did not cleave their targets. The cleaving DNAzymes specifically inhibited p210bcr-abl protein expression by chronic myeloid leukemia K562 cells by ~40%, and inhibited cell growth by >50% over a 6-day assay period. Cells were transfected



**Figure 2.** Attrition (inverse) pyramid depicting the processes involved in DNAzyme selection and testing.

with the GS2888 cationic liposomal reagent. In an assay using freshly isolated CD34<sup>+</sup> bone marrow cells from patients with chronic myeloid leukemia, the DNazymes specifically inhibited the growth of *bcr-abl*-positive colonies by up to 80%.

We examined the interaction between DNazymes and transfection reagents using a panel of human cancer cell lines (16). Altering DNAzyme size (17-33mer) and chemistry (phosphodiester, 4+4 arms phosphorothioate arms, or 3'-3'-inverted terminus) did not significantly affect uptake into cultured prostate, breast, and lung cancer cells. DNAzyme was distributed primarily in punctate structures surrounding the nucleus and substantial delivery to the nucleus was not observed up to 24 h after initiation of transfection using two cationic reagents, *N*-[1-(2,3-dioleoyloxy)propyl]-*N,N,N*-trimethylammoniummethyl sulfate and Superfect. Incubation in human serum showed that the 3'-3' inversion greatly increased DNAzyme stability ( $t_{1/2}$  ~22 h) compared with the unmodified form ( $t_{1/2}$  in the order of minutes). These results confirmed our earlier findings (17). The 3'-inversion-modified DNazymes remained stable during cellular (and nuclear) uptake, and functional oligonucleotide could be extracted from the cells 24 h posttransfection. The modified DNAzyme targeting the *c-myc* gene showed a more potent antiproliferation effect than did its unmodified sequence.

Cieslak and coworkers (36) designed DNazymes to  $\beta_1$  and  $\beta_3$  integrin mRNAs.  $\beta_1$  and  $\beta_3$  integrins are important in cell-cell and cell-matrix interactions in the pathogenesis of various tumors and other diseases. In the presence of Mg<sup>2+</sup>, both DNazymes cleaved their substrates, synthetic  $\beta_1$  and  $\beta_3$  mRNA fragments, specifically. Although DNazymes partially modified with phosphorothioate and with 2'-*O*-methyl groups at both the 5' and 3' ends indicated similar kinetics, they were significantly more potent

than the unmodified DNazymes because of their greater stability. The DNazymes inhibited microvascular endothelial cell capillary tube formation in fibrin and Matrigel, signaling their usefulness against tumor-induced angiogenesis.

The epidermal growth factor receptor is a receptor tyrosine kinase of the ErbB receptor family that is abnormally activated in many epithelial tumors (37). Beale et al. (38) used DNazymes that inhibited the growth of epidermal growth factor receptor-overexpressing A431 cancer cells in a dose-dependent manner when delivered with cationic lipids. Effects on cell growth were correlated in all cases with concomitant dose-dependent reduction in epidermal growth factor receptor protein expression.

DNazymes were synthesized to cleave the PML/RAR $\alpha$  transcript (39). Of note is that a quadruple transfection protocol was used by this group to attain ~80% down-regulation at the protein level. Two constructs cleaved PML/RAR $\alpha$  mRNA efficiently and specifically, and transfected cells exhibited a significant suppression of PML/RAR $\alpha$  protein expression. In cell-based assays using acute promyelocytic leukemia cells, the DNazymes inhibited proliferation and induced apoptosis in these cells.

Latent membrane protein, LMP1, encoded by EBV, is suggested to be one of the major oncogenic factors in EBV-mediated carcinogenesis. DNazymes targeting LMP1 were transfected (19) into B95-8 cells (established from peripheral blood lymphocytes of a Marmoset monkey and releasing high titers of EBV), which constitutively express LMP1. Tetramethylpyridyl porphyrin was used by the researchers to attain reasonable transfection efficiency. There was significant down-regulation of LMP1 and consequent inhibition of B95-8 cell growth at the G<sub>0</sub>-G<sub>1</sub> checkpoint. There was an interesting concomitant down-regulation of *bcl-2* gene expression, suggesting an association between

LMP1 and apoptosis. As confirmation of apoptosis, the DNazymes induce the release of cytochrome *c* from mitochondria.

A DNzyme targeting human survivin mRNA was evaluated in human pancreatic carcinoma PANC-1 cells (40). The DNzyme cleaved survivin mRNA efficiently in both a dose- and time-dependent manner. It achieved an ~80% decrease in target protein levels 72 h after a single transfection. It also pushed the cells into apoptosis and inhibited the growth of this cell line.

de Bock and coworkers (41) used three different DNzymes against urokinase-type plasminogen activator receptor (uPAR) mRNA, and were able to decrease target uPAR transcript *in vitro* by at least 84%. They also showed an ability to down-regulate uPAR mRNA in the human osteosarcoma cell line SaOS-2 after transfection. One DNzyme decreased uPAR mRNA within 4 h of transfection and inhibited uPAR protein concentrations by 55% in SaOS-2 cells with a triple transfection protocol. The decrease in uPAR mRNA and protein concentrations reduced SaOS-2 cell invasion in Matrigel. The use of DNzyme adds a new potential clinical agent for decreasing uPAR mRNA expression and inhibiting cancer invasion and metastasis.

These studies in cell culture show that different cancer gene targets can be successfully down-regulated whether they are endogenous (cell-expressed) or exogenous (virus-expressed) in a variety of cancer cell lines. Some of the effects in fact lead to anticancer activity as judged by phenotypical changes in cells. DNzymes are amenable to chemical modification, allowing them to be made more resistant against nuclease degradation and can be made to different arm lengths. These findings have helped pave the way for the *in vivo* evaluation of DNzymes.

### DNzymes as Antineoplastic Agents *In vivo*

Although no studies to date have been done in humans, several investigations done in animal disease models have proven the potential applicability of DNzymes in general and as discussed below, specifically against cancer (summarized in Table 1). Most of the studies have been done to prove whether these catalytic molecules can perform their function *in vivo*, and thereby extend their usefulness beyond the cell culture stage. Although *in vitro* assessment of DNzyme efficiency helps establish gene and sequence specificity, and is an expedited form of screening, important issues such as delivery, pharmacokinetics, metabolism, toxicity, and efficacy can only be examined *in vivo*. In the past 5 years, considerable progress has been made with these entities.

Cancers have traditionally been treated with agents that act on the neoplastic cells themselves in an attempt to halt proliferation or induce death due to apoptosis or necrosis. The alternative, and more recent approach, is to develop agents that act in an indirect manner against the tumor blood supply, and not the cancers themselves. Cancers are dependent on a blood vasculature for oxygen and

nutrients, and for waste removal just like a normal tissue, only more voraciously (42). Thus, various factors mediating angiogenesis induced by tumors have been targeted with DNzymes to inhibit neoplastic growth.

In a murine model, a DNzyme that targets the vascular endothelial growth factor receptor 2 (VEGFR2) mRNA transcript was found to cause an ~75% reduction of tumor size compared with the saline-injected control group (43). Marked cell death in the peripheral regions of the tumor accompanied by a reduction in blood vessel density was noted, being consistent with an antiangiogenic mechanism. Zhang et al. (43) first successfully applied this technology *in vivo* against tumors with DNzymes targeting VEGFR-2 attenuating tumor growth in rats. The DNzyme active against VEGFR-2 was injected intratumorally in a complex formulated from a histidine-lysine polymer.

In our hands, intratumorally administered DNzymes targeting Egr-1 also showed potent reduction in cancer growth with an associated reduction in tumor angiogenesis (44). A DNzyme against the zinc finger transcription factor Egr-1 blocked angiogenesis in s.c. Matrigel plugs in mice and in MCF-7 human breast tumors in nude mice. The DNzymes, complexed with a cationic reagent (Fugene6) did not exhibit any side effects that may occur using antiangiogenic agents, such as emaciation, perturbed wound healing, blood coagulation, or other hematologic variables. Furthermore, the Egr-1 DNzyme inhibited VEGF-induced neovascularization of the rat cornea. The DNzyme targeting the 5' untranslated region of the Egr-1 mRNA inhibited Egr-1 protein expression, microvascular endothelial cell replication and migration, and microtubule network formation on basement membrane matrices.

DNzyme activity against cancer is not limited to destruction of the tumor vasculature. We were the first to show the direct anticancer effects due to two different DNzyme entities. The first report (45) showed that Dz13, targeted against the basic region-leucine zipper protein c-Jun, blocked endothelial cell proliferation, migration, chemoinvasion, and tubule formation. The DNzymes were complexed with Fugene6 and coadministered with tumor cells. Dz13 inhibited endothelial cell expression and proteolytic activity of matrix metalloproteinase-2, a c-Jun-dependent gene. *In vivo*, Dz13 inhibited VEGF-induced neovascularization in the rat cornea and B16 melanoma growth in mice. There was a 2.5-fold decrease in tumor volume by Dz13 and a 60% decrease in the number of tumor-associated blood vessels in these mice. The decrease in corneal vascularization due to VEGF stimulus was 75% in the Dz13 group of rats.

A direct antitumor effect was achieved with an Egr-1 DNzyme complementary to the human Egr-1 mRNA sequence (46). This molecule, DzF, strongly inhibited Egr-1 expression in the MCF7 human breast carcinoma line, which correlated with inhibition of proliferation of these cells when induced by addition of serum back into the growth medium. DzF also inhibited both cellular migration (40%) and chemoinvasion (60%) in these cells. DzF was also capable of significantly reducing s.c. tumor growth when

**Table 1.** *In vivo* applications of DNAzymes in animal models of cancer

mRNA target	Animal	Xenograft	Delivery mode	Dose regimen	Anticancer activity	References
VEGFR-2	Mouse	MDA-MB-435	Intratumoral	Four injections of 30 $\mu$ L, each of 2.9 $\mu$ g of DNAzyme and 1.092 nmol his-lys polymer	75% reduction in tumor size, cell death in tumor periphery, reduction in blood vessel density	(44)
Egr-1	Mouse	MCF-7	Intratumoral	Twice a week, injections of 20 $\mu$ L, each of 20 $\mu$ g of DNAzyme and 1 $\mu$ L Fugene-6	80% reduction in tumor size, reduction in blood vessel density	(45)
c-Jun	Mouse	B16	Comixed with cell inoculation	Commencement of experiment, 750 $\mu$ g of Dz comixed with 2.5 $\mu$ L Fugene-6 reagent injected s.c.	60% reduction in tumor size, reduction in blood vessel density	(46)
Egr-1	Mouse	MDA-MB-231	Intratumoral	When tumors were palpable, single injection of 10 $\mu$ L, of 10 $\mu$ g of free DNAzyme	67% reduction in tumor size	(47)
c-Jun	Mouse	T79	Comixed with cell inoculation	Commencement of experiment, 50 $\mu$ g of Dz comixed with 2.5 $\mu$ L Fugene-6 reagent injected s.c.	90% reduction in tumor size	(48)

injected intratumorally once tumors were palpable at a dose of 10  $\mu$ g/injection twice a week. At termination, tumors were at least one third the volume of those in the control groups.

We have also more recently shown that the Dz13 DNAzyme is capable of reducing not only solid melanoma growth, but squamous cell carcinoma growth in mice as well (47). Dz13 down-regulated c-Jun expression in T79 cells and also inhibited their growth in a dose-dependent manner. In nude mice, when Dz13 was co-injected with T79 cells s.c. into the midback, tumor volumes in the Dz13-treated group decreased by 80%, and the blood vessel number in examined tumor sections were reduced by 40%. Importantly, the levels of c-Jun were significantly (80%) reduced by Dz13. The Dz13 molecule is a case in point in that once a potent down-regulation agent is found, with its inherent sequence-specific knockdown, then it may be found to possess applicability across various pathologies that are caused by expression or overexpression of the targeted gene. Further evidence of the antiangiogenic properties of Dz13 is shown by its inhibition of retinal neovascularization in mice induced by exposure to hyperoxia-normoxia (44). Dz13 also has the capacity to inhibit restenosis (48) and inflammation (49) in a variety of animal models consistent with c-Jun-targeting activity.

These studies collectively show the potential of DNAzymes as sequence-specific molecular tools. The number of studies using DNAzymes have increased quite substantially in the past 3 years (50, 51) with DNAzyme activity assessed in a variety of clinically relevant models. This will undoubtedly continue in coming years.

Although singular DNAzyme targets have been used in biological systems thus far, it is possible that greater biological efficacy may be achieved using combinations of DNAzymes and/or other small-molecule nucleic acid

strategies targeting the same factor or multiple factors. In cancer for instance, there is increasing realization that for effective and lasting tumor regression, resulting in increased patient quality of life, a combinatorial approach may be preferable in efforts to prevent neoplastic cells evolving mechanisms to avoid single agent-based therapy, which in itself may prove quite toxic (58). A tumor, by its very nature, is full of cells that are either quite different, or have the capacity to mutate to become quite different, some of these cells then acquiring the ability to resist chemotherapy. These strategies may include such combinations as DNAzymes against an oncogene together with the use of frontline chemotherapy. Such strategies have been successful in proving the efficacy (59, 60) of the *bcl-2* antisense molecule, G3139 (now Genasense).

The fact that DNAzymes possess a number of other advantages over other gene-silencing agents, including lower production cost, ease of chemical modification, and relative serum stability, makes them attractive therapeutic candidates for further development, and clinical evaluation. A key challenge to the use of DNAzymes as anticancer reagents is delivery to the site of disease.

### DNAzyme Delivery—Facing the Beast of a Challenge

The most important issue facing the therapeutic use of DNAzyme is tissue delivery after systemic administration. The DNAzyme needs to travel from its site of administration (Fig. 3), through the bloodstream, out of the circulation, through the tumor stroma, and acting against the high interstitial pressure common in tumors, directly into the cancer cells. Then, it must find its target mRNA and be able to annul its message.

DNA itself can act as a scaffold for the manufacture of some rather smart nanotechnologies, and this technology


reaches far back as 12 years ago (52, 53). With the aid of the “sticky ends” of DNA, dispersed three- and four-way DNA junctions and other structural blocks can be connected into large repeating structures, on which other entities such as nanoparticles or proteins can be deposited to form quite intricate and conforming patterns (54, 55). DNA has also been conjugated to inorganic nanoparticles to form structures with a limited number of particles or cross-linked aggregates of these particles (56, 57). When the potential of DNA to form such organized microstructures is taken into consideration, then the development of such delivery vehicles for DNAzymes presents an exciting challenge, the enormity notwithstanding.

The use of nanobiotechnology has blossomed into a large field, and some of this technology has trickled into the field of gene therapy as well. Solid nanoparticles formulated from such materials as atelocollagen (61), chitosan nanoparticles (62), and polypropylene imine (63) have served as alternative approaches to liposomes (64). It may well be that biophysical devices, such as those used for delivery of peptides (65), could aid DNAzyme delivery to the diseased site and minimize normal tissue exposure.

Thus far, only atelocollagen has been injected systemically and shown to deliver an small interfering RNA

sequence efficiently to growing tumors in mice (61). This study used a metastatic prostate cancer model where tumors deposit in the bone of mice. A series of three injections were made, each with 50  $\mu\text{g}$  of small interfering RNA against the reporter gene luciferase. Also, this group showed the ability of this technology to effect efficacy by using two targets that showed promise in *in vitro* assays. However, this technology is still in its early days, and more rigorous testing of its applicability to DNAzymes is surely warranted.

Small interfering RNA-encapsulating chitosan nanoparticles developed by Howard and coworkers (62) were capable of down-regulating a target gene in the bronchiole epithelial cells of mice after intranasal administration. Such an approach would be highly valuable for lung cancers or those that metastasize to the lungs such as osteosarcoma (66). To directly address the latter, two orthotopic spontaneously metastasizing models for osteosarcoma have recently been developed to evaluate the potential of novel therapeutic agents and delivery vehicles to target secondary pulmonary tumors (34, 67). Chitosan is an abundant material that is catching the eye of gene therapists (68) and has been shown to efficiently deliver plasmids via the oral route (69).



**Figure 3.** Route taken by free DNAzyme to down-regulate target gene in targeted cancer cells. 1, DNAzyme is administered via the blood supply. 2, DNAzyme is carried by blood circulation to the site of the lesion and other tissues. 3, DNAzyme extravasates through the capillaries and moves toward the cancer cells. 4, DNAzyme neutralizes its targeted mRNA in the nucleus or in the cytoplasm.

Recent developments suggest that light might be useful as an activation device for DNazymes and that perhaps some degree of targeting could arise by harnessing this phenomenon. This technology, however, has not progressed beyond the *in silico* stage, where light is directed to DNazymes in a cell-free system to test whether better activity can be attained. Liu and Sen (70) elegantly showed that depending on the strategic positioning (whether in the substrate binding arms or within the catalytic core) of azobenzene residues within the DNzyme, the DNzyme could either be induced to cleave or repressed when visible or UV light was used. Azobenzene can convert between its *cis* and *trans* forms as light is altered from UV to the visible range of the electromagnetic spectrum. The 5- to 6-fold higher rates of cleavage inducible by light is an astonishing feat, and there are plans to emulate this within cells. Ting and colleagues (71) used a photoactivatable adenosine analogue to show that when stimulated by UV light, cleavage activity was enhanced at least 5-fold, especially at 60 min. However, both the above two chemical modifications result in loss in enzymatic activity when compared with the nonmodified (parent) DNzyme.

To address this, Asanuma and coworkers (72) reported the enhancement of the inherent cleavage activity of active DNazymes by the covalent attachment of an intercalator such as azobenzene via an amide bond to D-threosinol, which inserts into the DNA backbone using typical phosphoramidate chemistry. The azobenzene chemistry gave a 3-fold increase in DNzyme activity in a cell-free system over the parent molecule; moreover, its activity was repressible when exposed to UV light. A more recent approach, using nitropiperonyloxymethyl chemistry, which is altered (deprotected) by UV light, was used to synthesize DNazymes that could potentially be activated in specific areas in cells or in the body (73).

Albeit DNzyme technology is in its relative infancy, progress thus far suggests the emergence of an exciting era of gene modulation, one that may be able to dramatically change bioactivity *in vivo*, and even be used to control molecular and cellular interactions relevant to disease and fill an unmet need where conventional drugs such as doxorubicin are accompanied by side effects.

## Summary

DNazymes have come a long way since their discovery a decade-and-a-half ago. From their earliest use as tools for molecular dissection, they have now progressed toward clinical evaluation. The main stumbling block, as for other antigene therapies, is the need to be able to complement methods for targeted delivery to tumors *in vivo*, so as to limit exposure of normal tissues and organs.

## References

1. Marwick C. First "antisense" drug will treat CMV retinitis. *JAMA* 1998;280:871.
2. Redorbit. [http://www.redorbit.com/news/health/696002/gentas\\_gentasense\\_gets\\_orphan\\_status/index.html](http://www.redorbit.com/news/health/696002/gentas_gentasense_gets_orphan_status/index.html), accessed on 2007 May 10.

3. Haseloff J, Gerlach W. Simple RNA enzymes with new and highly specific endoribonuclease activities. *Nature* 1988;334:585–91.
4. Khan AU. Ribozyme: a clinical tool. *Clin Chim Acta* 2006;367:20–7.
5. Breaker RR, Joyce GF. A DNA enzyme that cleaves RNA. *Chem Biol* 1994;1:223–9.
6. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. *Proc Natl Acad Sci U S A* 1997;94:4262–6.
7. Paterson BM, Roberts BE, Kuff EL. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. *Proc Natl Acad Sci U S A* 1977;74:4370–4.
8. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. *Proc Natl Acad Sci U S A* 1978;75:285–8.
9. Leonetti C, Zupi G. Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy. *Curr Pharm Des* 2007;13:463–70.
10. Masiero M, Nardo G, Indraccolo S, Favaro E. RNA interference: implications for cancer treatment. *Mol Aspects Med* 2007;28:143–66.
11. Gilbert W. The RNA world. *Nature* 1986;319:618.
12. Zaborowska Z, Furste JP, Erdmann VA, Kurreck J. Sequence requirements in the catalytic core of the "10-23" DNA enzyme. *J Biol Chem* 2002;277:40617–22.
13. Silverman SK. *In vitro* selection, characterization, and application of deoxyribozymes that cleave RNA. *Nucleic Acids Res* 2005;33:6151–63.
14. Santoro SW, Joyce GF. Mechanism and utility of an RNA-cleaving DNA enzyme. *Biochemistry* 1998;37:13330–42.
15. Cairns MJ, Hopkins TM, Witherington C, Wang L, Sun L-Q. Target site selection for an RNA-cleaving catalytic DNA. *Nat Biotechnol* 1999;17:480–6.
16. Dass CR, Saravolac EG, Li Y, Sun LQ. Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. *Antisense Nucleic Acid Drug Dev* 2002;12:289–99.
17. Santiago FS, Kavurma MM, Lowe HC, Chesterman CN, Atkins DG, Khachigian LM. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. *Nat Med* 1999;5:1264–9.
18. Sun LQ, Cairns MJ, Gerlach WL, Witherington C, Wang L, King A. Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme. *J Biol Chem* 1999;274:17236–41.
19. Lu ZX, Ye M, Yan GR, et al. Effect of EBV LMP1 targeted DNazymes on cell proliferation and apoptosis. *Cancer Gene Ther* 2005;12:647–54.
20. Wahlestedt C, Salmi P, Good L, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. *Proc Natl Acad Sci U S A* 2000;97:5633–8.
21. Fluiter K, ten Asbroek AL, de Wissel MB, et al. *In vivo* tumour growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. *Nucleic Acids Res* 2003;31:953–62.
22. Guvakova MA, Yakubov LA, Vlodayevsky I, Tonkinson JL, Stein CA. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. *J Biol Chem* 1995;270:2620–7.
23. Rockwell P, O'Connor WJ, King K, Goldstein NI, Zhang LM, Stein CA. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. *Proc Natl Acad Sci U S A* 1997;94:6523–8.
24. Vester B, Lundberg LB, Sorensen MD, Babu BR, Douthwaite S, Wengel J. LNazymes: incorporation of LNA-type monomers into DNazymes markedly increases RNA cleavage. *J Am Chem Soc* 2002;124:13682–3.
25. Schubert S, Gul DC, Grunert HP, Zeichhardt H, Erdmann VA, Kurreck J. RNA cleaving "10-23" DNazymes with enhanced stability and activity. *Nucleic Acids Res* 2003;31:5982–92.
26. Fahmy RG, Khachigian LM. Locked nucleic acid-modified DNA enzymes targeting early growth response-1 inhibit vascular smooth muscle cell growth. *Nucleic Acids Res* 2004;32:2281–5.
27. Koshkin AA, Wengel J. Synthesis of novel 2',3'-linked bicyclic thymine ribonucleosides. *J Org Chem* 1998;63:2778–1.
28. Braasch DA, Corey DR. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. *Chem Biol* 2001;8:1–7.



29. Kumar R, Singh SK, Koshkin AA, Rajwanshi VK, Meldgaard M, Wengel J. The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio-LNA. *Bioorg Med Chem Lett* 1998;8:2219–22.
30. Nielsen CB, Singh SK, Wengel J, Jacobsen JP. The solution structure of a locked nucleic acid (LNA) hybridized to DNA. *J Biomol Struct Dyn* 1999;17:175–91.
31. Petersen M, Nielsen CB, Nielsen KE, et al. The conformations of locked nucleic acids (LNA). *J Mol Recognit* 2000;13:44–53.
32. Fluiter K, Frieden M, Vreijling J, Koch T, Baas F. Evaluation of LNA-modified DNAzymes targeting a single nucleotide polymorphism in the large subunit of RNA polymerase II. *Oligonucleotides* 2005;15:246–54.
33. Schubert S, Kurreck J. Ribozyme- and deoxyribozyme-strategies for medical applications. *Curr Drug Targets* 2004;5:667–81.
34. Dass CR, Ek ET, Contreras KG, Choong PF. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. *Clin Exp Metastasis* 2006;23:367–80.
35. Wu Y, Yu L, McMahon R, Rossi JJ, Forman SJ, Snyder DS. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). *Hum Gene Ther* 1999;10:2847–57.
36. Cieslak M, Niewiarowska J, Nawrot M, Koziolkiewicz M, Stec WJ, Cierniewski CS. DNAzymes to  $\beta_1$  and  $\beta_3$  mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. *J Biol Chem* 2002;277:6779–87.
37. Arteaga CL, Baselga J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. *Clin Cancer Res* 2003;9:1579–89.
38. Beale G, Hollins AJ, Benboubetra M, et al. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. *J Drug Target* 2003;11:449–56.
39. Kabuli M, Yin JA, Tobal K. Targeting PML/RAR $\alpha$  transcript with DNAzymes results in reduction of proliferation and induction of apoptosis in APL cells. *Hematol J* 2004;5:426–33.
40. Liang Z, Wei S, Guan J, et al. DNAzyme-mediated cleavage of survivin mRNA and inhibition of the growth of PANC-1 cells. *J Gastroenterol Hepatol* 2005;20:1595–602.
41. de Bock CE, Lin Z, Itoh T, Morris D, Murrell G, Wang Y. Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. *FEBS J* 2005;272:3572–82.
42. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med* 1971;285:1182–6.
43. Zhang L, Gasper WJ, Stass SA, Ioffe OB, Davis MA, Mixson AJ. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. *Cancer Res* 2002;62:5463–9.
44. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. *Nat Med* 2003;9:1026–32.
45. Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ, Khachigian LM. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. *J Natl Cancer Inst* 2004;96:683–96.
46. Mitchell A, Dass CR, Sun LQ, Khachigian LM. Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1. *Nucleic Acids Res* 2004;32:3065–9.
47. Zhang G, Luo X, Sumithran E, Barnetson RS, Halliday GM, Khachigian LM. Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. *Oncogene* 2006;25:7260–6.
48. Khachigian LM, Fahmy RG, Zhang G, Bobryshev YV, Kaniaras A. c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. *J Biol Chem* 2002;277:22985–91.
49. Fahmy RG, Waldman A, Zhang G, et al. Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. *Nat Biotechnol* 2006;24:856–63.
50. Dass CR. Deoxyribozymes: cleaving a path to clinical trials. *Trends Pharmacol Sci* 2004;25:395–7.
51. Khachigian LM. Deoxyribozymes as inhibitors of vascular smooth muscle cell growth. *Curr Pharm Biotechnol* 2004;5:337–9.
52. Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ. A DNA-based method for rationally assembling nanoparticles into macroscopic materials. *Nature* 1996;382:607–9.
53. Alivisatos AP, Johnsson KP, Peng X, et al. Organization of "nanocrystal molecules" using DNA. *Nature* 1996;382:609–11.
54. Yan H, Park SH, Finkelstein G, Reif JH, LaBean TH. DNA-templated self-assembly of protein arrays and highly conductive nanowires. *Science* 2003;301:1882–4.
55. Sharma J, Chhabra R, Liu Y, Ke Y, Yan H. DNA-templated self-assembly of two-dimensional and periodical gold nanoparticle arrays. *Angew Chem Int Ed Engl* 2006;45:730–5.
56. Deng Z, Tian Y, Lee SH, Ribbe AE, Mao C. DNA-encoded self-assembly of gold nanoparticles into one-dimensional arrays. *Angew Chem Int Ed Engl* 2005;44:3582–5.
57. Zhao W, Gao Y, Kandadai SA, Brook MA, Li Y. DNA polymerization on gold nanoparticles through rolling circle amplification: towards novel scaffolds for three-dimensional periodic nanoassemblies. *Angew Chem Int Ed Engl* 2006;45:2409–13.
58. Ek ET, Choong PF. The role of high-dose therapy and autologous stem cell transplantation through rolling circle amplification: towards novel scaffolds for three-dimensional periodic nanoassemblies. *Angew Chem Int Ed Engl* 2006;45:2409–13.
59. Badros AZ, Goloubeva O, Rapoport AP, et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexame-thasone and thalidomide in relapsed multiple myeloma patients. *J Clin Oncol* 2005;23:4089–99.
60. Tolcher AW, Chi K, Kuhn J, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. *Clin Cancer Res* 2005;11:3854–61.
61. Takeshita F, Minakuchi Y, Nagahara S, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen *in vivo*. *Proc Natl Acad Sci U S A* 2005;102:12177–82.
62. Howard KA, Rahbek UL, Liu X, et al. RNA interference *in vitro* and *in vivo* using a novel chitosan/siRNA nanoparticle system. *Mol Ther* 2006;14:476–84.
63. Tack F, Bakker A, Maes S, et al. Modified poly(propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). *J Drug Target* 2006;14:69–86.
64. Dass CR. Liposome-mediated delivery of oligodeoxynucleotides *in vivo*. *Drug Deliv* 2002;9:169–80.
65. Dass CR, Choong PF. Biophysical delivery of peptides: applicability for cancer therapy. *Peptides* 2006;27:3479–88.
66. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. *Cancer Treat Rev* 2006;32:423–36.
67. Luu HH, Kang Q, Park JK, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. *Clin Exp Metastasis* 2005;22:319–29.
68. Dass CR, Contreras KG, Dunstan DE, Choong PF. Chitosan micro-particles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma. *Biomaterials* 2007;28:3026–33.
69. Zheng F, Shi XW, Yang GF, et al. Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an *in vitro* and *in vivo* study. *Life Sci* 2007;80:388–96.
70. Liu Y, Sen D. Light-regulated catalysis by an RNA-cleaving deoxyribozyme. *J Mol Biol* 2004;341:887–92.
71. Ting R, Lermer L, Perrin DM. Triggering DNAzymes with light: A photoactive C8 thioether-linked adenosine. *J Am Chem Soc* 2004;126:12720–1.
72. Asanuma H, Hayashi H, Zhao J, et al. Enhancement of RNA cleavage activity of 10-23 DNAzyme by covalently introduced intercalator. *Chem Commun Camb* 2006;48:5062–4.
73. Lusic H, Young DD, Lively MO, Deiters A. Photochemical DNA activation. *Org Lett* 2007;9:1903–6.